ALK status in a primary lung tumour and metachronous metastases

Histopathology

Volumn 60, Issue 5, 2012, Pages 843-845

  Salido, Marta ^a   Pijuan, Lara ^a   Galván, Ana B ^a   Gimeno, Javier ^a   Cañadas, Israel ^a   Rodriguez Rivera, Maria ^a   Rojo, Federico ^a,b   Albanell, Joan ^a   Solé, Francesc ^a   Arriola, Edurne ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UAM)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; KI 67 ANTIGEN; THYROID TRANSCRIPTION FACTOR 1;

ADRENALECTOMY; AGED; ASPIRATION BIOPSY; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOPATHOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPHADENECTOMY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SMOKING; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; AGED; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; LYMPH NODE EXCISION; MALE; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84859009452     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04100.x     Document Type: Letter

References (6)

1. Grande E, Bolos MV, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol. Cancer Ther. 2011; 10; 569-579.
2. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363; 1693-1703.
3. Salido M, Pijuan L, Martinez-Aviles L et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 2011; 6; 21-27.
4. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448; 561-566.
5. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 2010; 363; 1727-1733.
6. Gow CH, Chang YL, Hsu YC et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann. Oncol. 2009; 20; 696-702.